| Molecular Formula: | |
|---|---|
| Molecular Formula | C22H17ClN6O |
| Molecular Weight: | |
| Molecular Weight | 416.86 |
| COA: | |
| COA | Inquire |
| Targets: | |
| Targets | PI3K |
| Description: | |
| Description | The R isomer analogue of Duvelisib which is a high selective PI3K δ/γ inhibitor. |
| Purity: | |
|---|---|
| Purity | 95% |
| Appearance: | |
| Appearance | Powder |
| Synonyms: | |
| Synonyms | IPI-145 R enantiomer; IPI 145 R enantiomer; IPI145 R enantiomer; INK1197 R enantiomer; INK 1197 R enantiomer; INK-1197 R enantiomer |
| Solubility: | |
| Solubility | DMSO |
| Storage: | |
| Storage | -20ºC Freeze |
| MSDS: | |
| MSDS | Inquire |
| Application: | |
| Application | The R isomer analogue of Duvelisib which is a high selective PI3K δ/γ inhibitor. |
| Shelf Life: | |
| Shelf Life | As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly |
| Quantity: | |
|---|---|
| Quantity | Milligrams-Grams |
| InChIKey: | |
| InChIKey | SJVQHLPISAIATJ-CYBMUJFWSA-N |
| InChI: | |
| InChI | InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m1/s1 |
| Canonical SMILES: | |
| Canonical SMILES | CC(C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5 |
Related PI3K Products
BGT226 (NVP-BGT226)
(CAS: 1245537-68-1)
BGT226 (NVP-BGT226) is a novel class I PI3K/mTOR inhibitor for PI3Kα/β/γ with IC50 of 4 nM/63 nM/38 nM. Phase 1/2.
PQR530
(CAS: 1927857-61-1)
PQR530 is a potent dual pan PI3K/mTOR inhibitor undergoing phase II clinical trials in 2016. Aberrant activation of the PI3K/mTOR signaling pathway promotes the...
CH5132799
(CAS: 1007207-67-1)
CH5132799 is a novel class I PI3K inhibitor, which exhibited a strong inhibitory activity especially against PI3K; (IC(50)=0.014 uM). In human tumor cell lines ...
AM-8508
(CAS: 1338483-67-2)
AM-8508 is a selective Phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor. AM-8508 exhibits good cellular potency (in vitro pAKT IC50 = 4.6 nM ) and excellen...
Acalisib
(CAS: 870281-34-8)
Acalisib, also known as GS-9820, is an inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) ...
PF-4989216
(CAS: 1276553-09-3)
PF-4989216 is a novel potent and selective PI3K inhibitor. PF-4989216 inhibits the phosphorylation of PI3K downstream molecules and subsequently leads to inhib...
NSC 66389,3-MA
(CAS: 5142-23-4)
copanlisib hydrochloride
(CAS: 1402152-13-9)
Copanlisib hydrochloride is a potent inhibitor of Class I phosphoinositide 3-kinase which showed a therapeutic effect on non-Hodgkin lymphoma. It was approved t...
LY 294002 hydrochloride
(CAS: 934389-88-5)
LY 294002 hydrochloride is a PI 3-kinase inhibitor with IC50 values of 0.31μM for PI 3-Kβ, 0.73μM for PI 3-Kα, 1.06μM for PI 3-Kδ and 6.60μM for PI 3-Kγ. It can...
ETP-46321
(CAS: 1252594-99-2)
ETP-46321 is a potent and orally bioavailable PI3K α, δ inhibitor with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after o...
PI3Kα inhibitor 1
(CAS: 1235449-52-1)
PI3Kα inhibitor 1 is an inhibitor of PI3Kα as well as HDAC and probably have antineoplastic activity. IC50: ＜0.1 μM.
ZSTK474
(CAS: 475110-96-4)
ZSTK474 is a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, which strongly inhibits cancer cell proliferation. Phosphoinositide 3-kinase (PI3K) is a pote...
SAR-405
(CAS: 1523406-39-4)
SAR-405 is a potent and selective inhibitor of phosphoinositide 3-kinase (PI3K) class III isoform Vps34 (IC50= 1.2 nM, Kd= 1.5 nM) without disrupting other PI3K...
Pilaralisib
(CAS: 934526-89-3)
Pilaralisib, also known as XL147, is a methylbenzenesulfonamide derivative that reversibly inhibits class I PI3Ks (IC50s = 39, 36, 23, and 383 nM for p110α, δ, ...
TGR-1202
(CAS: 1532533-67-7)
TGR-1202, also known as RP5264, is a highly specific, orally available, PI3Kdelta inhibitor which is approximately 1000 -fold selective over alpha isoform, >30-...
CAL-101 (GS-1101)
(CAS: 870281-82-6)
Idelalisib is a kinase inhibitor. In combination with rituximab, it was used for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).